<DOC>
	<DOCNO>NCT02876848</DOCNO>
	<brief_summary>Background : In woman hormone receptor positive ( HR+ ) breast cancer , adjuvant endocrine therapy ( AET ) associate significant survival advantage . Nonadherence particular challenge old woman , even though stand benefit AET . Therefore , novel e-health tool ( OPTIMUM ) integrate real-time analysis health administrative claim data develop provide point-of-care decision support clinician .</brief_summary>
	<brief_title>A Novel E-Health Approach Optimizing Treatment Seniors ( OPTIMUM Study )</brief_title>
	<detailed_description>Objectives : 1 ) To determine effectiveness patient-specific , real-time e-health alert deliver point-of-care reduce rate AET discontinuation understand patient-level factor relate AET discontinuation . 2 ) To assess integration e-health alert regard deviation best practice administration AET cancer care team . Methods : A prospective , two group control comparison pilot study conduct two urban , McGill University-affiliated hospital , Royal Victoria Hospital St. Mary 's Hospital . A minimum 43 patient per study arm enrol site-level allocation . Follow-up 1.5 year . Healthcare professional intervention site access e-health tool report real-time : medical event know association AET discontinuation , AET adherence monitor , discontinuation alert .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Selective Estrogen Receptor Modulators</mesh_term>
	<criteria>1 . Must ≥ 65 year old , 2 . Have diagnose incident ( nonmetastatic ) breast cancer , 3 . Have histologicallyconfirmed breast adenocarcinoma , 4 . Have undergone breast surgery stag IIII disease , 5 . Have medical insurance Régie de l'Assurance Maladie du Québec ( RAMQ ) least 1 year prior surgery , 6 . Have HR positive disease , 7 . Have history AET use prior diagnosis breast cancer , 8 . Expected initiate AET recently initiate AET ( &lt; 6 month ) free previous discontinuation event , 9 . Have ability consent . male gender</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Administrative Claims , Healthcare</keyword>
	<keyword>Aromatase Inhibitors</keyword>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Health Services Aged</keyword>
	<keyword>Medical Informatics Applications</keyword>
	<keyword>Medication Adherence</keyword>
	<keyword>Outcome Process Assessment ( Health Care )</keyword>
	<keyword>Selective Estrogen Receptor Modulators</keyword>
	<keyword>Telemedicine</keyword>
</DOC>